Cite
P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer.
MLA
Oh, Do-Youn, et al. “P5-5 Phase 2/3 Study of Bintrafusp Alfa with Gemcitabine plus Cisplatin as First-Line Treatment of Biliary Tract Cancer.” Annals of Oncology, vol. 32, July 2021, p. S333. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.05.684.
APA
Oh, D.-Y., de Braud, F., Bridgewater, J., Furuse, J., Hsu, C.-H., Ikeda, M., Lee, S., Moehler, M., Park, J. O., Shen, L., Yoo, C., Helwig, C., Osada, M., & Borad, M. (2021). P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology, 32, S333. https://doi.org/10.1016/j.annonc.2021.05.684
Chicago
Oh, Do-Youn, Filippo de Braud, John Bridgewater, Junji Furuse, Chih-Hung Hsu, Masafumi Ikeda, Sunyoung Lee, et al. 2021. “P5-5 Phase 2/3 Study of Bintrafusp Alfa with Gemcitabine plus Cisplatin as First-Line Treatment of Biliary Tract Cancer.” Annals of Oncology 32 (July): S333. doi:10.1016/j.annonc.2021.05.684.